Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib switch study after ocrelizumab in relapsing multiple sclerosis
2023-509275-17-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of remibrutinib and ocrelizumab in multiple sclerosis (MS) (3 arms), sponsored by Novartis. Primary endpoint: Annualized rate of new or enlarging T2 lesions on MRI at Month 24. Planned start Aug 2025; status: authorised.
02
Drugs
remibrutinibocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-509275-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509275-17-00.